Gina P. Lundberg

Omega-3 Fatty Acid Blood Levels Clinical Significance Update

ABSTRACTThe potential benefit of fish oil (omega-3 fatty acids) consumption to reduce cardiovascular disease (CVD) risk remains controversial. Some investigations report reduced CVD risk associated with fish or fish oil consumption while others report no benefit. This controversy is in part resolved when consideration is given to omega-3 blood levels in relation to CVD risk as well as blood levels achieved in clinical trials of omega-3 supplementation and CVD benefit. There is a wide variation in omega-3 blood levels achieved between individuals in response to a given dose of an omega-3 supplement. Many studies tested a daily dose of 1 gram omega-3 supplementation. The individual variation in blood omega-3 levels achieved in response to a fixed daily dose helps to explain why some individuals may obtain CVD protection benefit while others do not due to failure to achieve a therapeutic threshold. Recent development of a population range in a United States population helps to provide clinical guidance since population omega-3 blood level ranges may vary due to environmental and genetic reasons. Omega-3 supplementation may also be of benefit in reducing the adverse impact of air pollution on CVD risk.

Coronary Revascularization in Women

Historically, mortality rates have been higher in women than in men for both PCI and CABG. Recent registries and studies have shown that women have mortality rates similar to men after correcting for age and comorbidities. The gender gap is narrowing with respect to outcomes for women with both PCI and CABG. Revascularization with PCI and CABG in women with stable angina (SA), unstable angina (UA), non ST‐elevation myocardial infarction (NSTEMI), and ST‐elevation myocardial infarction (STEMI) will all be reviewed in light of the most recent studies and registries.

Burden of stroke in women.

Stroke is the fifth cause of death in the United States and the first cause of disability. While reductions in stroke mortality have occurred, stroke remains a significant burden in women. In addition to traditional cardiovascular risk factors, there are specific risk factors in women that need to be addressed to further reduce deaths in women from stroke. Atrial fibrillation is common in women and needs proper evaluation for anticoagulation for risk reduction. Stroke in women remains a serious cause of preventable deaths, disability, and cost. Implementation of the new guidelines for stroke prevention in women is critical for reducing the burden of stroke in women.

Sex Differences in Ischemic Heart Disease: Advances, Obstacles, and Next Steps

Evolving knowledge of sex-specific presentations, improved recognition of conventional and novel risk factors, and expanded understanding of the sex-specific pathophysiology of ischemic heart disease have resulted in improved clinical outcomes in women. Yet, ischemic heart disease continues to be the leading cause of morbidity and mortality in women in the United States. The important publication by the Institute of Medicine titled “Women’s Health Research—Progress, Pitfalls, and Promise,” highlights the persistent disparities in cardiovascular disease burden among subgroups of women, particularly women who are socially disadvantaged because of race, ethnicity, income level, and educational attainment. These important health disparities reflect underrepresentation of women in research, with the resultant unfavorable impact on diagnosis, prevention, and treatment strategies in women at risk for cardiovascular disease. Causes of disparities are multifactorial and related to differences in risk factor prevalence, access to care, use of evidence-based guidelines, and social and environmental factors. Lack of awareness in both the public and medical community, as well as existing knowledge gap regarding sex-specific differences in presentation, risk factors, pathophysiology, and response to treatment for ischemic heart disease, further contribute to outcome disparities. There is a critical need for implementation of sex- and gender-specific strategies to improve cardiovascular outcomes. This review is tailored to meet the needs of a busy clinician and summarizes the contemporary trends, characterizes current sex-specific outcome disparities, delineates challenges, and proposes transformative solutions for improvement of the full spectrum of ischemic heart disease clinical care and research in women.

Lipoprotein(a) and Increased Cardiovascular Risk in Women

Approximately 20% of the population has elevated circulating levels of lipoprotein(a) (Lp[a]), one of the most robust predictors of cardiovascular disease risk. This is particularly true for women.

Sex-Specific Differences in Risk Factors for Development of Heart Failure in Women

Sex specific differences exist in the impact of risk factors for the development of heart failure (HF). Addressing these differences can have an impact on prevention of HF. This article reviews sex-specific risk factors associated with development of HF. These risk factors include current smoking, diabetes, hypertension, and myocardial infarction. Other risks for HF are toxins, inflammation, and other chronic conditions, such as sleep breathing disorders, anemia, obesity, and renal insufficiency. Some of these risks factors present risk reduction opportunities that may improve outcomes.

Specialized Care for Women: the Impact of Women’s Heart Centers

Purpose of the reviewCardiovascular disease (CVD) has been and remains the leading cause of mortality in women in the United States. For decades, more women died every year of CVD compared to men. Heart centers for women (HCW) are developed in response to the need for greater patient and physician awareness of CVD in women and to conduct sex-specific research in women. Today, many HCW provide multispecialty and focused areas of cardiovascular care for women. HCW provide their female patients with expertise over the many stages of a woman’s life. And HCW partner with national organizations to advance research and education through specialized and focused care for women. The purpose of this review is to review the historical development of heart centers for women and discuss the types of care they provide for women.Recent findingsMortality rates from cardiovascular disease in women are finally reaching the levels of men after decades of focus on awareness, prevention, and evidence-based guideline-directed care for women.SummaryHeart centers for women have evolved to provide subspecialty and comprehensive care for women that includes education and research. Heart centers for women are partnering with many other disease-based and patient advocacy organizations to provide care for all women at all stages of life. Alarmingly, there has been increasing CVD mortality in both men and women recently.

JCL roundtable: Cardiovascular disease risk reduction in menopausal women

Ovarian failure occurs in most women during the late fifth decade or early sixth decade of life. This causes a number of changes in physiology as estrogen and progestin concentrations decline. These involve lipoprotein metabolism and the vasculature. The risk factors for large vessel disease increase, and dysfunction of the small resistance vessels responds with changes in blood flow to the skin causing unpleasant symptoms. These and other changes result in visits to the physician. A reassessment of risk factors and symptoms is needed to develop a new plan for effective management, both short term and long term.